In a groundbreaking development poised to transform biomedical research and therapeutic innovation, scientists from the Singapore-MIT Alliance for Research and Technology (SMART) have engineered the world’s first automated tool designed to comprehensively analyze RNA chemical modifications—specifically transfer RNA (tRNA) modifications—across thousands of biological samples. This pioneering technology ushers in a new era in epitranscriptomics, the study of over 170 diverse chemical modifications decorating RNA molecules, which play critical roles in regulating gene expression, cellular function, and organismal responses to environmental stress and disease.
Central to this advancement is the tool’s unprecedented capacity to rapidly profile tRNA modifications using a fully automated pipeline, integrating robotic liquid handling with high-precision liquid chromatography-tandem mass spectrometry (LC-MS/MS). This combination notably reduces the manual effort, cost, and hazardous chemical exposure that have long hindered scalable studies of RNA modifications. The implications are far-reaching: by unlocking the hidden regulatory networks encoded in RNA chemical marks, researchers are now empowered to decode complex cellular adaptations in diseases such as cancer and antibiotic-resistant infections.
Chemical modifications on tRNAs, which serve as molecular adaptors in protein synthesis, fine-tune cellular responses to a myriad of physiological challenges, including oxidative stress, nutrient scarcity, and microbial invasion. Until now, profiling these modifications system-wide at high throughput remained a formidable challenge due to inherently labor-intensive protocols and technical limitations. The SMART-developed platform overcomes these obstacles by automating sample preparation and data acquisition for tens of thousands of samples, facilitating a scale of investigation previously unattainable.
Demonstrating the capabilities of their system, researchers applied it to over 5,700 genetically modified strains of Pseudomonas aeruginosa, a notorious pathogen responsible for a variety of infections including pneumonia and sepsis. The automated analysis generated more than 200,000 high-resolution data points, revealing novel RNA-modifying enzymes and detailed mapping of epitranscriptomic regulatory networks. Such insights illuminate how bacterial cells navigate hostile environments, adapt metabolically, and resist antibiotics—processes central to infection persistence and treatment failure.
A standout discovery enabled by this platform involves the methylthiotransferase MiaB, an enzyme critical for the tRNA modification ms2i6A. The data indicated that MiaB activity is intricately modulated by intracellular iron and sulfur availability, and oxygen tension, reflecting a sophisticated mechanism by which bacteria sense and respond to microenvironmental changes. This nuanced understanding could catalyze the identification of new antimicrobial targets and lead to therapies that subvert bacterial survival strategies.
Beyond infectious disease, this technology holds transformative potential for cancer research. RNA modifications are increasingly recognized as pivotal regulators of oncogenic pathways, influencing tumor growth, metastasis, and response to therapy. By enabling rapid, expansive epitranscriptome profiling, the SMART tool equips scientists with a powerful means to discover biomarkers for early detection, prognosis, and therapeutic stratification in oncology.
The methodological innovation lies not only in throughput but in the safety and reproducibility gains achieved. Traditional tRNA modification analyses frequently rely on toxic solvents like phenol and chloroform, posing health risks and variability in results. The SMART platform’s integrated robotics automate enzymatic digestion and sample processing steps, obviating manual handling of hazardous compounds, thus setting a new standard for laboratory safety and experimental consistency.
This comprehensive, system-wide approach provides a holistic snapshot of the epitranscriptome, a level of insight that surpasses targeted analyses traditionally employed. By capturing quantitative profiles of multiple tRNA modifications concurrently, the technology reveals interconnected regulatory circuits and post-transcriptional modifications that govern gene expression dynamics under normal and pathological states.
The implications extend into pharmaceutical and biotechnological realms, where this tool offers a strategic advantage for drug development and screening. Pharmaceutical companies can deploy high-throughput RNA modification profiling to evaluate candidate drugs’ effects on epitranscriptomic landscapes, accelerating biomarker discovery and optimizing therapeutic efficacy with greater precision.
As co-lead Principal Investigator Prof. Peter Dedon emphasized, this innovation transforms how researchers decode RNA’s regulatory language, with the potential to unravel complex gene networks involved in cancer progression and antimicrobial resistance. Such knowledge is critical for designing next-generation diagnostics and interventions tailored to patient-specific molecular profiles, embodying the promise of personalized medicine.
Looking ahead, the SMART AMR team envisions extending the platform’s application beyond microbial models to human cells and tissues. By interrogating human epitranscriptomes at scale, researchers can deepen understanding of disease mechanisms, identify novel clinical biomarkers, and propel development of customized treatment regimens. This transfer from bench to bedside signifies a crucial step in translating epitranscriptomic research into tangible healthcare solutions.
Supported by the National Research Foundation Singapore’s CREATE program, this development exemplifies successful interdisciplinary collaboration, uniting expertise from bioengineering, molecular biology, mass spectrometry, and computational analytics. The confluence of these fields has culminated in a tool that responds to pressing global health challenges by accelerating discovery and translational research in RNA biology.
In sum, the SMART-developed automated tRNA modification profiling system is a landmark technological advancement that paves the way for high-throughput epitranscriptomic studies. Its ability to rapidly and safely assay RNA chemical modifications at scale promises to revolutionize fundamental biological research, expedite drug discovery pipelines, and usher in a new paradigm of precision medicine targeting RNA regulatory mechanisms in cancer and infectious diseases.
Subject of Research: Cells
Article Title: tRNA modification profiling reveals epitranscriptome regulatory networks in Pseudomonas aeruginosa
News Publication Date: 3 September 2025
Web References:
https://smart.mit.edu/research/amr/about-amr
https://smart.mit.edu/
https://academic.oup.com/nar/article/53/14/gkaf696/8213826
References:
Dedon, P., Sun, J. et al. (2025). tRNA modification profiling reveals epitranscriptome regulatory networks in Pseudomonas aeruginosa. Nucleic Acids Research, 53(14). DOI: 10.1093/nar/gkaf696
Image Credits: SMART AMR
Keywords: Biomedical engineering, Cancer cells, Cells, Cancer, RNA, Transfer RNA
